Acorda Announces Phase 1 Results for Remyelinating Antibody in Multiple Sclerosis

Acorda Announces Phase 1 Results for Remyelinating Antibody in Multiple Sclerosis

Acorda Therapeutics, Inc. has released results from a Phase 1 clinical trial of rHIgM22 for multiple sclerosis, showing that the medication is safe and produces few side effects.

shutterstock_235097353 (2)rHIgM22 is a medication that may induce the re-wrapping of the myelin sheath that surround nerve cells, allowing them to conduct impulses from one to the other. The symptoms of multiple sclerosis are believed to be due to an immune attack on the body’s own myelin, which can cause unpredictable loss of movement, sensation, vision problems and feelings of pain.

The medication rHIgM22 is a recombinant human monoclonal antibody that was originally identified in the laboratory of Moses Rodriguez, M.D. at the Mayo Clinic. In animals, rHIgM22 protected oligodendrocytes, the cells that produce myelin, from death. It also caused oligodendrocytes to repair regions of the nervous system that had lost myelin. With rHIgM22 treatment, animals with experimental MS also regained some motor function.

The Phase 1 study lasted up to six months. In the first phase, fifty participants with any type of MS received a single dose of rHIgM22, with five dose different dose levels studied by the researchers. Eight people were given each dose, and two per dose group were given placebo. None of the doses caused excessive side effects compared to the placebo, or problems that would limit the use of this medication. During the study, people with MS continued on any medication that they were taking for the condition.

[adrotate group=”4″]

In the second study phase, 21 people with MS who had never received any medication for the condition received either placebo or one of the two highest doses of rHIgM22. The study subjects were examined for six months. Again the medication was found by the investigators to be safe and tolerable. In the second part of the study clinical, imaging and biomarker measurements were also taken. This data is still being analyzed and will be released later.

Overall, the most common side effects were: headache, contact dermatitis, MS relapse, infusion site hematoma, fatigue, arthralgia, back pain, muscular weakness, neck pain, pain in an extremity, pruritus, contusion, and flushing. No participants dropped out of the study due to these side effects.

Acorda will continue to develop the medication based on these results. Anthony Caggiano, M.D., Ph.D., Acorda’s Senior Vice President of Research and Development stated “We’re encouraged by the outcome of this trial, which showed that rHIgM22 was well-tolerated at all of the dose levels we studied. We are currently developing the protocol for our next Phase 1 clinical trial of rHIgM22. The data from this study will help inform the design of the next trial, which will enroll people with MS who are experiencing an active relapse.”


  1. Henry says:

    Dr. Alisa Woods, Thank you for your update. I am wondering if they observed any motor functions changes in patients when they collected safety data in the last six months.

    When will they release topline results of efficacy?

  2. Alisa Woods, PhD says:

    The primary purpose of the Phase 1 study was to examine safety and tolerability. No efficacy results are available from Acorda at this time and it is not clear that efficacy results will be released from this particular study. They may release further results from the study (nothing is out just yet), but to really get a handle on efficacy we will probably have to wait for a Phase 2 trial at the very least. The study is not powered to examine efficacy and is really a stepping stone to set up parameters for future studies with more subjects.

  3. Alan Carpenter says:

    When will this drug be available? Does it also matter if someone is jc virus positive? I’m a 39 yr old single father and would love to try anything that could possibly change my current the situation

  4. JM says:

    My neuro at UCSF has asked me to participate in the 2nd round of Phase 1 for RHIgM22…I’m not sure what my decision will be because since dx (04/15), safety has been my first priority. I really wish this was at least Phase 2 but it looks like FIH trial didn’t have any SAEs in the drug group, just placebo. Any thoughts would be appreciated 🙂 oh and p.s. I am also JC+ so that is my main concern and the reason I am still not on any DMDs.

Leave a Comment

Your email address will not be published. Required fields are marked *